{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"BRAF V600E"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"BRAF V600K"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"BRAF V600D"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"BRAF V600R"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Other V600"}],"denoms":[{"counts":[{"groupId":"OG000","value":"548"}],"units":"Participants"}],"description":"FFPEs tumor samples (at least 5 serially-cut, unstained, 5 μm sections) were collected from eligible participants who consented to participate in the study. FFPE tumor samples were either from archived sections (from the initial diagnosis of cancer) or from fresh biopsies that were performed according to local standards. Tumor samples were then sent to a central laboratory to identify activating BRAF V600 mutations. Identification of mutations was done using bidirectional direct Sanger sequencing procedure. V600E, V600K, V600D, and V600R are the different types of BRAF V600 mutations.","groups":[{"description":"Participants with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma who met the inclusion criteria and did not meet exclusion criteria of the study were enrolled and were evaluated for the presence of BRAF V600 mutations by collecting tumor samples or performing fresh biopsies according to local standards.","id":"OG000","title":"Participants With Confirmed Solid Tumors or Multiple Myeloma"}],"paramType":"NUMBER","populationDescription":"All the participants who were enrolled and were evaluable for the BRAF V600 mutations were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Number of Participants Classified Based on Different Types of BRAF V600 Mutation Patterns in Tumor Samples","type":"PRIMARY","unitOfMeasure":"participants"}